
The Atlanta Braves should make free-agent right-hander Nick Pivetta a priority this winter, with one condition. Signing him cannot be their entire solution to a depleted starting rotation.
Pivetta offers a chance to add a pitcher capable of starting meaningful October games without committing to a lengthy contract. His recent elbow trouble also demands that Atlanta build a rotation capable of surviving his absence.
President of baseball operations Alex Anthopoulos should pursue both goals. The Braves need more quality innings, but they also need enough alternatives when their preferred starters become unavailable.
The San Diego Padres declined Pivetta’s $14 million club option for 2027, making him a free agent. That creates an opportunity Atlanta should investigate carefully.
Pivetta’s strongest selling point is the quality of his recent work.
In 2025, he went 13-5 with a 2.87 ERA and 190 strikeouts across 181 2/3 innings. He made 31 starts and finished sixth in National League Cy Young Award voting.
His abbreviated 2026 season offered further evidence of his effectiveness. Pivetta finished 3-2 with a 2.86 ERA, 1.01 WHIP, and 42 strikeouts against eight walks in 34 2/3 innings.
Those numbers establish a meaningful distinction between Pivetta and a pitcher signed simply to compete for the fifth rotation spot. When available, he has recently delivered the production Atlanta should want alongside ace Chris Sale.
The concern is substantial. A right elbow flexor strain limited Pivetta to eight regular-season starts in 2026. He also missed time with a flexor strain in 2024.
The Braves would be paying for his ability while accepting uncertainty about how often they could use it.
That makes his medical evaluation central to the decision. Strong recent results justify pursuing him. They do not justify assuming his elbow problems are behind him.
Atlanta’s postseason exposed the consequences of running short on healthy starters.
The Braves won 94 games and the NL East before losing to the Los Angeles Dodgers in the NL Division Series. Sale and Tyler Mahle were their only traditional starting options during that series.
Mahle is now a free agent, creating another decision for Anthopoulos.
Meanwhile, Anthopoulos’ recent injury updates offered different outlooks for Spencer Strider and Spencer Schwellenbach. Strider is on track for spring training or the season’s start. Schwellenbach is unlikely to be ready when the season begins.
The Braves should offer Pivetta one year and $15 million guaranteed, with another $3 million available through incentives tied to innings pitched.
This proposed deal would allow Pivetta to rebuild his market value before returning to free agency. Atlanta would pay a meaningful salary while limiting its commitment to one season.
The guarantee would still carry risk, making a favorable medical evaluation essential. Anthopoulos should also preserve enough flexibility to add another starter.
Pivetta could give the Braves another pitcher worth handing the ball to in October. Pairing that upside with additional rotation depth would make this a calculated investment the Braves should pursue.
More must-reads:
+
Get the latest news and rumors, customized to your favorite sports and teams. Emailed daily. Always free!